<DOC>
	<DOC>NCT01254565</DOC>
	<brief_summary>The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of KAI-4169 in hemodialysis subjects for the treatment of secondary hyperparathyroidism.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Subject provides written informed consent. Intact PTH at least 350 pg/mL. Corrected calcium at least 9.0 mg/dL. Hemoglobin at least 9.0 g/dL. Adequate hemodialysis three times per week. Excepting chronic renal failure, subject is judged to be in stable medical condition based on medical history, physical examination, and routine laboratory tests. History or symptomatic ventricular dysrhythmias. History of angina pectoris or congestive heart failure History of myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months. History of or treatment for seizure disorder. Recent (3 months) parathyroidectomy. Serum transaminases (alanine aminotransferase, aspartate aminotransferase) greater than two times the upper limit of normal at screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Clinical Trial, Phase 2</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>